Shanxi C&Y Pharmaceutical Group Co Ltd (300254) — Tangible Net Worth Ratio
Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has a Tangible Net Worth Ratio of 64.5% as of September 2025. This metric is calculated by deducting intangible assets (CN¥204.82 Million) from net assets (CN¥577.09 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Shanxi C&Y Pharmaceutical Group Co Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Shanxi C&Y Pharmaceutical Group Co Ltd Tangible Net Worth Ratio (2008–2024)
This chart shows how Shanxi C&Y Pharmaceutical Group Co Ltd's Tangible Net Worth Ratio has changed across 17 annual periods from 2008 to 2024. As of September 2025, the ratio stands at 64.5%, reflecting net assets of CN¥577.09 Million with intangible assets of CN¥204.82 Million CNY. See 300254 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Shanxi C&Y Pharmaceutical Group Co Ltd (2008–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2024, covering 17 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see 300254 market cap.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 65.2% | CN¥598.18 Million | CN¥208.11 Million | CN¥1.55 Billion | ▼ -8.0 pp |
| 2023 | 73.2% | CN¥778.43 Million | CN¥208.80 Million | CN¥1.43 Billion | ▲ +3.7 pp |
| 2022 | 69.5% | CN¥729.68 Million | CN¥222.63 Million | CN¥1.58 Billion | ▲ +1.1 pp |
| 2021 | 68.4% | CN¥744.58 Million | CN¥235.23 Million | CN¥1.53 Billion | ▼ -2.0 pp |
| 2020 | 70.4% | CN¥872.61 Million | CN¥258.38 Million | CN¥1.80 Billion | ▼ -16.7 pp |
| 2019 | 87.1% | CN¥932.60 Million | CN¥120.25 Million | CN¥1.80 Billion | ▲ +0.5 pp |
| 2018 | 86.6% | CN¥931.24 Million | CN¥124.46 Million | CN¥1.50 Billion | ▼ -0.1 pp |
| 2017 | 86.7% | CN¥971.17 Million | CN¥128.84 Million | CN¥1.52 Billion | ▲ +2.0 pp |
| 2016 | 84.8% | CN¥954.85 Million | CN¥145.40 Million | CN¥1.43 Billion | ▼ -4.6 pp |
| 2015 | 89.4% | CN¥872.50 Million | CN¥92.37 Million | CN¥1.31 Billion | ▲ +0.4 pp |
| 2014 | 89.1% | CN¥823.16 Million | CN¥90.07 Million | CN¥1.18 Billion | ▲ +2.5 pp |
| 2013 | 86.6% | CN¥767.16 Million | CN¥102.96 Million | CN¥1.09 Billion | ▲ +0.9 pp |
| 2012 | 85.7% | CN¥651.17 Million | CN¥93.25 Million | CN¥827.16 Million | ▼ -7.8 pp |
| 2011 | 93.5% | CN¥581.17 Million | CN¥37.65 Million | CN¥702.56 Million | ▲ +21.0 pp |
| 2010 | 72.6% | CN¥149.59 Million | CN¥41.05 Million | CN¥280.84 Million | ▼ -1.3 pp |
| 2009 | 73.9% | CN¥117.60 Million | CN¥30.69 Million | CN¥259.51 Million | ▼ -0.9 pp |
| 2008 | 74.8% | CN¥106.70 Million | CN¥26.88 Million | CN¥224.15 Million | — |